Related Experiment Video

Updated: Mar 7, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

Intergenically Spliced Chimeric RNAs in Cancer

Yuemeng Jia1, Zhongqiu Xie1, Hui Li1,2

  • 1Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908.

Trends in Cancer
|February 18, 2017
PubMed

Insights

Cancer hallmarks include gene fusions, but new research reveals chimeric RNAs can form without DNA changes. These findings impact cancer detection and therapy development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gene fusions are key cancer indicators, traditionally linked to chromosomal rearrangements.
  • Recent findings show chimeric RNAs can arise from splicing, not just DNA alterations.
  • Chimeric RNAs also occur in normal physiology, complicating cancer diagnostics.

Purpose of the Study:

  • To review current knowledge on chimeric RNAs in cancer.
  • To explore their implications for cancer detection and treatment.
  • To identify outstanding questions for future research.

Main Methods:

  • Literature review of gene fusion mechanisms.
  • Analysis of studies on chimeric RNA formation (trans-splicing, cis-splicing).
  • Evaluation of diagnostic and therapeutic applications of fusion RNAs.

Main Results:

  • Chimeric RNAs can be generated through splicing mechanisms independent of DNA rearrangement.
  • "Intergenically spliced" fusion RNAs present novel biomarker and therapeutic opportunities.
  • The presence of chimeric RNAs in normal tissues necessitates refined detection strategies.

Conclusions:

  • Chimeric RNAs, originating from various mechanisms, offer new avenues for cancer biomarkers and therapies.
  • Further research is needed to fully understand their roles and optimize clinical applications.
  • Distinguishing cancer-specific from physiological chimeric RNAs is crucial for effective use.
Keywords:
Chimeric RNAcis-SAGefusionintergenic splicingtrans-splicing

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.5K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.0K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
61.0K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.1K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
25.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.7K